Equillium announces presentation at the 3rd annual cytokine-based drug development summit

La jolla, calif.--(business wire)---- $eq--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced a presentation at the 3rd annual cytokine-based drug development summit. the presentation highlights equillium's multi-cytokine inhibitor technology and platform, and applications of cytokine technology beyond oncology. data on the platform, including th
EQ Ratings Summary
EQ Quant Ranking